Navigation Links
Proacta Incorporated Announces IND Allowance for PR610
Date:8/29/2012

SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.

The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed resistance to reversible tyrosine kinase inhibitors such as erlotinib and /or gefitinib. In such cases, no effective treatment is currently available.

The first clinical study will be conducted at sites in the US and New Zealand. Proacta expects to initiate patient enrollment in the coming weeks.

About PR610

PR610 is Proacta's proprietary hypoxia-activated irreversible MKI discovered at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. Reversible MKI's are currently used for the treatment of several types of cancer. However, resistance often develops to reversible MKI's and side effects limit their use at higher doses.

PR610 utilizes an irreversible MKI that is activated in areas of severe hypoxia, a characteristic of most solid tumors. Localized release of the irreversible MKI within tumors leads to higher tumor concentrations and lower concentrations in normal tissues, which should result in improved efficacy and fewer side effects. In addition, irreversible MKI inhibitors are not affected by some of the resistance mechanisms that limit use of reversible MKI inhibitors.

In subsequent studies, Proacta expects to evaluate PR610 in other cancers that are currently treated with first-generation reversible tyrosine kinase inhibitors such as gastric, breast, and pancreatic.

In 2011, Proacta engaged in the collaboration for research, development and commercialization of PR610 in Japan with Yakult Honsha Co., Ltd
'/>"/>

SOURCE Proacta
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accuray Incorporateds CEO to Speak at Morgan Stanley Global Healthcare Conference
2. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
3. Accuray Incorporated to Speak at Wells Fargo Healthcare Conference
4. Accuray Incorporated to Speak at Jefferies Global Healthcare Conference
5. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
6. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
7. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
8. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
9. Tribogenics Announces Dual-Energy X-ray Source for XRF
10. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
11. Cynosure Announces Upcoming Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... issuance of an aggregate of 30,000 stock options to ... of 120,500 stock options to employees and consultants of ... years and will be exercisable for a period of ... stock option. About Covalon Covalon Technologies ...
(Date:3/27/2015)... -- Object recognition technology has a unique and powerful ... VelaSense ® mobile platform incorporates applications ... and fulfilling lives. VelaSense ® will now incorporate ... objects from a one million object database, that is ... for personal use. Visus Technology ...
(Date:3/27/2015)... March 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... been appointed to the Company,s Board of Directors effective March ... in November 2014 of board member Joseph Barton .  ... to our Board of Directors represents an important step forward ... and president of Dynatronics.  "Rich is a proven leader and ...
Breaking Medicine Technology:Covalon Announces Issuance of Stock Options 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2
... DNDN ) will host a conference call tomorrow, ... AM PT) to review the outcome of the FINAL ... also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), ... of advanced prostate cancer. Those interested may access ...
... Binding Capabilities for Antibody Pipeline And Novel Technologies ... (Toronto Stock Exchange: IXS.V, http://www.ixsbio.com ), a ... monoclonal antibodies based on its technology, Dynamic Cross ... be presenting new data on its lead preclinical ...
Cached Medicine Technology:Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial 2AACR Data Highlights InNexus Preclinical Antibody Candidate 2
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 The ... method of sustainable health. After 18 years of research ... including professional UFC contenders, Dr. Jon Petrick is excited ... , Just some of the immediate benefits of this ... vitality, increased levels of strength of the immune system, ...
(Date:3/28/2015)... March 28, 2015 Purity Products®, ... supplements announces the release of their revolutionary new ... in two randomized, double-blind, placebo-controlled clinical studies to ... and hip size. MuffinStop™ is a combination of ... Garcinia mangostana, fused together to create one of ...
(Date:3/27/2015)... The Monogamy Method - ... Sanderson and Jason Rogers has just been released to ... The commotion surrounding the course's launch has caught the ... an in-depth review of the new program. , "Many ... their lives suddenly start pulling away or expressing interest ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership ... care provider for the 2015 and 2016 season. As the ... and an athletic trainer for the team throughout each season. ... against the Cleveland Gladiators at Amalie Arena; the game starts ... to us as it gives us the opportunity, to provide ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3
... Novavax Inc. (Nasdaq: NVAX) announced ... 12.5 million shares of Novavax,s common stock at $0.88 per share ... the new strategic alliance between Novavax and Cadila. Novavax intends to ... pay a portion of its 4.75% senior convertible notes due in ...
... that it reduces replication of the virus, , , WEDNESDAY, ... help people with HIV who don,t respond to standard ... the "gold standard" treatment for HIV is known as ... a number of drugs that reduce viral load by ...
... America (HFA) announces the publication of Living ... addition to HFA,s Living With Grief(R) book series. ... is a compilation of chapters by well-known experts in grief ... end-of-life decision making, shapes attitudes around the experience of terminal ...
... Albert Einstein College of Medicine of Yeshiva University have proposed ... brains of people with autism are structurally normal but dysregulated, ... , The central tenet of the theory, published in the ... autism is a developmental disorder caused by impaired regulation of ...
... schizoaffective disorder who received paliperidone extended release tablets ... in a broad range of schizoaffective symptoms, according ... 12th International Congress on Schizophrenia Research (ICOSR) in ... provide additional evidence for symptomatic improvement of schizoaffective ...
... April 1st, Professional Healthcare Resources celebrates 15 years of ... The company was started in 1994 by Eileen DeCesare ... an organization offering home health, hospice, and personal care ... The company has over 700 employees and eight branch ...
Cached Medicine News:Health News:Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals 2Health News:New HIV Drug May Help Those Resistant to Therapy 2Health News:Hospice Foundation of America Publishes New Book on Diversity and End-of-Life Care 2Health News:Einstein scientists propose new theory of autism 2Health News:Einstein scientists propose new theory of autism 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6Health News:Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 7Health News:Professional Healthcare Resources Celebrates 15 Year Anniversary 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: